Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer
European Journal of Cancer · 2026-11 · 248 · 117529
DOI: 10.1016/j.ejca.2026.117529 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von X. Chen und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chen, X., Wang, D., Li, Q., Fan, F., Liu, W., Xi, W., Zhou, L., Xu, L., Li, M., Xiang, J., & Zhang, Z. (2026). Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer. European Journal of Cancer, 248, 117529. https://doi.org/10.1016/j.ejca.2026.117529
Vancouver
Chen X, Wang D, Li Q, Fan F, Liu W, Xi W, et al. Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer. European Journal of Cancer. 2026;248:117529. doi:10.1016/j.ejca.2026.117529
BibTeX
@article{Chen2026,
author = {Chen, X. and Wang, D. and Li, Q. and Fan, F. and Liu, W. and Xi, W. and Zhou, L. and Xu, L. and Li, M. and Xiang, J. and Zhang, Z.},
title = {Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117529},
doi = {10.1016/j.ejca.2026.117529}
}
EUVIMED